The results of transrectal prostate biopsy in patients with low levels of prostate specific antigen

Abstract

Objectives: The aim of this study is to evaluate the results of prostate biopsy of patients who had the prostate-specific antigen (PSA) levels below 4 ng/ml. Material and methods: The medical records of 63 patients who underwent transrectal prostate biopsy, between January 2005 and December 2011, due to suspicion of prostate cancer with the PSA levels under 4 ng/ml were retrospectively reviewed. Results: Transrectal Prostate biopsy was performed to 63 patients. Prostate cancer was detected in 12 (19%) patients. The mean value of PSA was 2.5 ng/ml. The Gleason score of Prostate cancer patients was 6,8 (5-7) and the number of positive cores were 3. Conclusions: The rate of prostate cancer was found as 19% in patients with levels of PSA under 4 ng/ml and this ratio is compatible with the results of previous reports.

Keywords

• Prostate cancer, prostate-specific antigen, prostate biopsy

The results of transrectal prostate biopsy in patients with low levels of prostate specific antigen

Abstract

Amaç: Bu çalışmanın amacı, prostat spesifik antijen (PSA) değerleri 4 ng/ml altında olan hastaların prostat biyopsi sonuçlarını değerlendirmektir. Gereç ve yöntem: Kliniğimizde Ocak 2005-Aralık 2011 tarihleri arasında prostat kanseri şüphesi olan ve total PSA değeri 4 ng/ml\'nin altında olan 61 hastadan alınan prostat biyopsisinin sonuçları retrospektif olarak değerlendirildi. Bulgular: Yaşları 41 ile 74 arasında değişen ve PSA ortalaması 2.5 ng/ml olan 63 olguya Transrektal Ultrasonografi (TRUS) eşliğinde prostat biyopsisi yapıldı. On iki hastada (%19) prostat kanseri tespit edildi. Biyopsi sonucu prostat kanseri olan bu hastaların ortalama Gleason skoru 6.8 (5-7), tümor pozitif kor sayısı ise 3 idi. Sonuç: Prostat spesifik antijen değeri 4 ng/ml\'nin altında olan olgularda kanser oranımız %19 olup, önceki raporlarla uyumlu bulunmuştur.

Keywords

• Prostat Kanseri, prostat spesifik antijen, prostat biyopsi

References

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16(3):481-88.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58(1):71-96.
3. Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treat- ment of clinically localised disease. European urology 2011; 59(1):61-71.
4. Cooner WH, Mosley BR, Rutherford CL, Jr., et al. Prostate cancer detection in a clinical urological practice by ultraso- nography, digital rectal examination and prostate specific antigen. J Urol 1990; 143(8):1146-52.
5. Catalona WJ, Smith DS, Ratliff TL, et al. Detection of organ- confined prostate cancer is increased through prostate-spe- cific antigen-based screening. JAMA 1993; 270(7):948-54.
6. Mettlin C, Lee F, Drago J, et al. The American Cancer Soci- ety National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer 1991; 67(11):2949-58.
7. Colberg JW, Smith DS, Catalona WJ. Prevalence and path- ological extent of prostate cancer in men with prostate specific antigen levels of 2.9 to 4.0 ng./ml. J Urol 1993; 149(3):507-09.
8. Lodding P, Aus G, Bergdahl S, et al. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen. J Urol 1998; 159(6):899-903.

9. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324(9):1156-61.
10. Schroder FH, van der Cruijsen-Koeter I, de Koning HJ, et al. Prostate cancer detection at low prostate specific anti- gen. J Urol 2000; 163(6):806-12.
11. Carter HB, Pearson JD. Prostate-specific antigen testing for early diagnosis of prostate cancer: formulation of guide- lines. Urology 1999; 54:780-6.
12. Catalona WJ, Hudson MA, Scardino PT, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994; 152(11):2037-42.
13. Ross KS, Carter HB, Pearson JD, et al. Comparative ef- ficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA 2000; 284(8):1399-405.
14. Morgan TO, Jacobsen SJ, McCarthy WF, et al. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 1996; 335(2):304-10.
15. Altunoluk B, Bahar MR, Eren M, et al. Evaluation of the role of digital rectal examination and prostate specific anti- gen in diagnosis of prostate cancer J Clin Exp Invest 2012; 3(1):66-70.
16. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer de- tection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997; 277:1452-55.
17. Gilbert SM, Cavallo CB, Kahane H, et al. Evidence suggest- ing PSA cutpoint of 2.5 ng/mL for prompting prostate biop- sy: review of 36,316 biopsies. Urology 2005; 65(3):549-53.
18. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific an- tigen level < or =4.0 ng per milliliter. N Engl J Med 2004; 350(10):2239-46.
19. Thompson IM, Ankerst DP, Chi C, et al. Operating charac- teristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005; 294(1):66- 70.
20. Leite KR, Srougi M, Dall’Oglio MF, et al. Histopathologi- cal findings in extended prostate biopsy with PSA < or = 4 ng/mL. Int Braz J Urol 2008; 34(3):283-90.